Abstract
Opioids induce respiratory depression via activation of μ-opioid receptors at specific sites in the central nervous system including the pre-Bötzinger complex, a respiratory rhythm generating area in the pons. Full opioid agonists like morphine and fentanyl affect breathing with onset and offset profiles that are primarily determined by opioid transfer to the receptor site, while the effects of partial opioid agonists such as buprenorphine are governed by transfer to the receptor site together with receptor kinetics, in particular dissociation kinetics. Opioid-induced respiratory depression is potentially fatal but may be reversed by the opioid receptor antagonist naloxone, an agent with a short elimination half-life (30 min). The rate-limiting factor in naloxone-reversal of opioid effect is the receptor kinetics of the opioid agonists that requires reversal. Agents with slow dissociation kinetics (buprenorphine) require a continuous naloxone infusion while agents with rapid kinetics (fentanyl) will show complete reversal upon a single naloxone dose. Since naloxone is non-selective and will reverse analgesia as well, efforts are focused on the development of compounds that reverse opioid-induced respiratory depression without affecting analgesic efficacy. Such agents include ampakines and serotonin agonists which are aimed at selectively enhancing central respiratory drive. A novel approach is aimed at the reduction of respiratory depression from opioid-activation of (micro-)glia cells in the pons and brainstem using micro-glia cell stabilizers. Since this approach simultaneously enhances opioid analgesic efficacy it seems an attractive alternative to the classical reversal strategies with naloxone.
Keywords: Ventilatory control, opioid receptor, opioid receptor agonist, opioid receptor antagonist, morphine, fentanyl, buprenorphine, naloxoxe, glia, half-life.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Opioid-induced Respiratory Depression
Volume: 18 Issue: 37
Author(s): Merel Boom, Marieke Niesters, Elise Sarton, Leon Aarts, Terry W. Smith and Albert Dahan
Affiliation:
Keywords: Ventilatory control, opioid receptor, opioid receptor agonist, opioid receptor antagonist, morphine, fentanyl, buprenorphine, naloxoxe, glia, half-life.
Abstract: Opioids induce respiratory depression via activation of μ-opioid receptors at specific sites in the central nervous system including the pre-Bötzinger complex, a respiratory rhythm generating area in the pons. Full opioid agonists like morphine and fentanyl affect breathing with onset and offset profiles that are primarily determined by opioid transfer to the receptor site, while the effects of partial opioid agonists such as buprenorphine are governed by transfer to the receptor site together with receptor kinetics, in particular dissociation kinetics. Opioid-induced respiratory depression is potentially fatal but may be reversed by the opioid receptor antagonist naloxone, an agent with a short elimination half-life (30 min). The rate-limiting factor in naloxone-reversal of opioid effect is the receptor kinetics of the opioid agonists that requires reversal. Agents with slow dissociation kinetics (buprenorphine) require a continuous naloxone infusion while agents with rapid kinetics (fentanyl) will show complete reversal upon a single naloxone dose. Since naloxone is non-selective and will reverse analgesia as well, efforts are focused on the development of compounds that reverse opioid-induced respiratory depression without affecting analgesic efficacy. Such agents include ampakines and serotonin agonists which are aimed at selectively enhancing central respiratory drive. A novel approach is aimed at the reduction of respiratory depression from opioid-activation of (micro-)glia cells in the pons and brainstem using micro-glia cell stabilizers. Since this approach simultaneously enhances opioid analgesic efficacy it seems an attractive alternative to the classical reversal strategies with naloxone.
Export Options
About this article
Cite this article as:
Boom Merel, Niesters Marieke, Sarton Elise, Aarts Leon, W. Smith Terry and Dahan Albert, Non-Analgesic Effects of Opioids: Opioid-induced Respiratory Depression, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582469
DOI https://dx.doi.org/10.2174/138161212803582469 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Vitamin D Analogs Modulating the Pocket Structure of Vitamin D Receptor
Current Topics in Medicinal Chemistry Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of New 1,3-diphenyl-3- (phenylamino)propan-1-ones as Selective Cyclooxygenase (COX-2) Inhibitors
Medicinal Chemistry Disordered Interactome of Human Papillomavirus
Current Pharmaceutical Design The Shielding Action of Disaccharides for Typical Proteins in Aqueous Solution Against Static, 50 Hz and 1800 MHz Frequencies Electromagnetic Fields
Current Chemical Biology Anticancer Properties of Asian Water Monitor Lizard (Varanus salvator), Python (Malayopython reticulatus) and Tortoise (Cuora kamaroma amboinensis)
Anti-Cancer Agents in Medicinal Chemistry The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Anti-Aging Property of G2013 Molecule as a Novel Immunosuppressive Agent on Enzymatic and Non-Enzymatic Oxidative Stress Determinants in Rat Model
Current Drug Discovery Technologies High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design The Application of Micro-Analytical Techniques to Biomedical Analysis
Current Pharmaceutical Analysis Design and Structure of Peptide and Peptidomimetic Antagonists of Protein- Protein Interaction
Current Protein & Peptide Science Affinity-Based Methods in Drug-Target Discovery
Current Drug Targets Synthesis, Characterization, Antimycobacterial and Anticancer Evaluation of New 1,2,4-Triazole Derivatives
Letters in Drug Design & Discovery The Evaluation of Multivariate Adaptive Regression Splines for the Prediction of Antitumor Activity of Acridinone Derivatives
Medicinal Chemistry Applications of luminous bacteria enzymes in toxicology
Combinatorial Chemistry & High Throughput Screening Circulating Meteorin-like Levels in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis
Current Pharmaceutical Design Evidences of Monomer, Dimer and Trimer of Recombinant Human Cyclophilin A
Protein & Peptide Letters Beyond Numbers: The Informative Patterns of Immuno-Staphylococcal Dynamics
Current Pharmaceutical Design Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science The Concurrent Therapeutic Potential of Adipose-derived Mesenchymal Stem Cells on Gentamycin-induced Hepatorenal Toxicity in Rats
Current Stem Cell Research & Therapy